Atopic Dermatitis (AD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Atopic dermatitis (AD) is a chronic inflammatory skin disease of multifactorial etiology characterized by age-specific skin lesions, xerosis, and highly pruritic outbreaks. Usually starting in early childhood, AD significantly reduces patients’ quality of life. Patients with AD are more susceptible to the development of allergic diseases and frequently suffer from multimorbidity. Multiple studies link AD during infancy to the future appearance of asthma and allergic rhinitis, with 80% of patients eventually developing either of them or both. Food allergies occur in 35% of children with AD, and cutaneous infections and keratoconjunctivitis are more frequent than in the general population.

·       According to the International Study of Asthma and Allergies in Childhood estimates, AD globally affects 15%–20% of children and 1%–3% of adults. These prevalence figures are growing worldwide and show clear geographical variances; AD is more frequent in industrialized and high-income countries than in agriculture-based ones with low incomes.

·       The most frequent chronic comorbidities in children with AD of all ages and for both sexes were asthma (13.1%), psychosocial disorders (7.9%), visual impairment (7.8%), congenital anomalies of limbs (5.8%), and developmental disorders (3.2%), among others. All these comorbidities were more prevalent in the population with AD. Upper respiratory tract infections (54.4%), otitis media (12.8%), conjunctivitis (10.1%), and pharyngitis (7.9%) were amongst the most prevalent acute conditions in this atopic cohort.

 

The competitive landscape of Atopic Dermatitis (AD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Atopic Dermatitis (AD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atopic Dermatitis (AD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Atopic Dermatitis (AD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Dupilumab        Regeneron Pharmaceuticals      Phase 3

2          KHK4083          Kyowa Kirin Pharmaceutical Development, Inc.            Phase 2

3          ISB 830 Ichnos Sciences SA       Phase 2

4          Baricitinib          Eli Lilly and Company    Phase 3

5          DS-2741a         Daiichi Sankyo Co., Ltd. Phase 1

6          Upadacitinib      AbbVie  Phase 3

7          Tradipitant        Vanda Pharmaceuticals Phase 3

8          Etrasimod         Arena Pharmaceuticals  Phase 2

9          MEDI3506        AstraZeneca     Phase 2

10        AMTX-100 CF   Amytrx Therapeutics, Inc.          Phase 2

Continue.
 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more